Adlai Nortye adds two oncologists to scientific advisory board

Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology company, has appointed Dr. David S. Hong and Dr. Piro Lito to its Scientific Advisory Board, according to a company statement.

Dr. Hong serves as the Douglas E. Johnson Endowed Professor and Deputy Chair in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He received his M.D. from Albert Einstein College of Medicine and completed his oncology fellowship at MD Anderson. He has authored hundreds of peer-reviewed publications and received awards including the Amgen Young Investigator Award and the Jesse H. Jones Award.

Dr. Lito holds the Enid A. Haupt Chair in Therapeutic Research and serves as Director of Basic and Translational Research in the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. He earned his M.D. and Ph.D. from Michigan State University. His research contributed to the FDA approval of the first-in-class KRAS G12C inhibitors. He has received the Trailblazer Prize for Clinician Scientists from the Foundation of the National Institutes of Health and the ASCI Seldin-Smith Award for Pioneering Research.

Adlai Nortye's pipeline includes AN9025, an oral pan-RAS(ON) inhibitor; AN4035, a CEACAM5-targeting antibody drug conjugate; and AN8025, a tri-specific immuno-oncology candidate.

You May Also Be Interested In

• Niagen Bioscience's Tru Niagen now sold at GNC and Sam's Club
• Maris-Tech receives repeat order from government intelligence customer
• Cosmos Health signs Saudi distribution deal for supplement line